Latanoprost Teva-Ratiopharm (Latanoprost)

Latanoprost acts as a prostaglandin F2α analog that binds to FP receptors in the eye’s ciliary body. This binding triggers remodeling of the extracellular matrix, enhancing the uveoscleral outflow of aqueous humor, which in turn reduces intra‑ocular pressure.

The prescribed dose of latanoprost is determined by the treating eye‑care professional. Typically, one drop is instilled into the affected eye(s) once daily in the evening, but the exact regimen should follow the prescriber’s instructions.

Safety data for latanoprost in pregnancy and lactation are limited. It should only be used if the potential benefit justifies the potential risk to the fetus or infant, and the decision should be made in consultation with a healthcare provider.

To place an order, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies, and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details, and necessary import documentation.

Latanoprost belongs to the prostaglandin analog class, which generally offers once‑daily dosing and strong intra‑ocular pressure reduction. Compared with beta‑blockers or carbonic anhydrase inhibitors, prostaglandin analogs often have a more favorable dosing schedule and comparable efficacy, though individual response may vary.

Latanoprost eye drops should be stored at room temperature, away from direct sunlight and moisture. Keep the bottle tightly closed, protect it from light, and do not freeze. Discard any solution that appears discolored or contains particles.

Latanoprost is administered as a single drop placed in the conjunctival sac of the affected eye(s) once daily, usually in the evening. The patient should wash hands before use, avoid touching the tip of the bottle to any surface, and close the eyelids gently after instillation.

Serious risks, though rare, include severe allergic reactions such as angio‑edema, uveitis, corneal edema, macular edema, and sudden loss of vision. Any signs of severe eye pain, redness, or visual changes should prompt immediate medical evaluation.

Latanoprost should not be used by individuals with active ocular infections, hypersensitivity to latanoprost or any component of the formulation, or by patients who are currently using other prostaglandin analog eye drops without medical supervision.